Synthesis and biochemical properties of 8-amino-6-fluoro-9-beta-D-ribofuranosyl-9H-purine. 1986

J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery

The synthesis and characterization of 8-amino-6-fluoro-9-beta-D-ribofuranosyl-9H-purine (3a) are presented. This compound is a substrate for adenosine deaminase and adenosine kinase. In L1210 cells 3a is converted to 8-aminoinosine monophosphate (4b), apparently by the action of AMP deaminase on the monophosphate of 3a, as well as to the triphosphate derivative of 3a. Pentostatin was used to inhibit adenosine deaminase, and coformycin was used to inhibit AMP deaminase in experiments designed to delineate the metabolic fate of 3a. Pentostatin was without influence on the cytotoxicity of 3a, but coformycin potentiated the cytotoxicity. The potentiation was associated with an increased cellular concentration of phosphates of 3a and a decreased concentration of 4b.

UI MeSH Term Description Entries
D007291 Inosine Monophosphate Inosine 5'-Monophosphate. A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. IMP,Inosinic Acid,Ribosylhypoxanthine Monophosphate,Inosinic Acids,Sodium Inosinate,Acid, Inosinic,Acids, Inosinic,Inosinate, Sodium,Monophosphate, Inosine,Monophosphate, Ribosylhypoxanthine
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D011684 Purine Nucleosides Purines with a RIBOSE attached that can be phosphorylated to PURINE NUCLEOTIDES. Purine Nucleoside,Nucleoside, Purine,Nucleosides, Purine
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003070 Coformycin A ribonucleoside antibiotic synergist and adenosine deaminase inhibitor isolated from Nocardia interforma and Streptomyces kaniharaensis. It is proposed as an antineoplastic synergist and immunosuppressant.
D000659 AMP Deaminase An enzyme that catalyzes the deamination of AMP to IMP. EC 3.5.4.6. AMP Aminase,Adenylate Deaminase,5'-AMP Deaminase,AMP Aminohydrolase,Myoadenylate Deaminase,5' AMP Deaminase,Aminase, AMP,Aminohydrolase, AMP,Deaminase, 5'-AMP,Deaminase, AMP,Deaminase, Adenylate,Deaminase, Myoadenylate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
March 2004, Bioorganic & medicinal chemistry,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
March 2004, Organic & biomolecular chemistry,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
April 2000, Nucleosides, nucleotides & nucleic acids,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
April 1965, Journal of the American Chemical Society,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
January 2021, Nucleosides, nucleotides & nucleic acids,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
January 1995, Nucleic acids symposium series,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
January 1973, Journal of the Chemical Society. Perkin transactions 1,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
January 1966, Journal of medicinal chemistry,
J A Secrist, and L L Bennett, and P W Allan, and L M Rose, and C H Chang, and J A Montgomery
March 1967, Biochimica et biophysica acta,
Copied contents to your clipboard!